Notably, recent evidence suggests a potential association between CFTR modulation and alterations in immune response and systemic inflammation, which may influence the development of comorbidities that are traditionally less emphasized in CF, such as cancer and metabolic diseases [6,7,8]. The gene discussed is CFTR; the disease is cancer.